Apimeds Pharmaceuticals US, Inc. (APUS): Capital Expenditures

Annual figures by period end, from SEC filings.

$57.3K

Year ended 2025-12-31

$53.4K

Trailing 12 months to 2026-06-30

Period ended	Capital Expenditures	Change YoY	Source filing
2025-12-31	$57.3K	n/a	2026-05-04, From 2025-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Capital Expenditures	Change YoY
Apimeds Pharmaceuticals US, Inc. (APUS)	2025-12-31	$57.3K	n/a
Transcode Therapeutics, Inc. (RNAZ)	2025-12-31	$6.7K	-69.4%
Gyre Therapeutics, Inc. (GYRE)	2025-12-31	$1.19M	-48.6%
Climb Bio, Inc. (CLYM)	2025-12-31	$186.0K	n/a
Aclaris Therapeutics, Inc. (ACRS)	2025-12-31	$111.0K	-8.3%
Aquestive Therapeutics, Inc. (AQST)	2025-12-31	$562.0K	+253.5%
Corbus Pharmaceuticals Holdings, Inc. (CRBP)	2025-12-31	$7.0K	n/a
Boundless Bio, Inc. (BOLD)	2025-12-31	$546.0K	-78.5%
Gossamer Bio, Inc. (GOSS)	2025-12-31	$79.0K	n/a

Compare APUS, RNAZ, GYRE, CLYM side by side · Screen every company in Pharmaceutical Preparations ↗